Since the initial clinical approval in the late 1990s and remarkable anticancer effects for
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …

Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …

Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …

Renal cell carcinoma (RCC) is the most common form of kidney cancer. It is categorized into
various subtypes, with clear cell RCC (ccRCC) representing about 85% of all RCC tumors …

Resistance to conventional and target specific antitumor drugs still remains one of the major
cause of treatment failure and patience death. This condition often involves ATP-binding …

Renal cell carcinoma (RCC) is characterized by an infrequent number of somatic mutations.
By contrast, epigenetic aberrations are commonly found in RCC, indicating that epigenetic …

Abstract Background Tyrosine kinase inhibitors (TKIs) such as sunitinib are multitarget
antiangiogenic agents in clear cell renal cell carcinoma (ccRCC). They are widely used in …

Renal cell carcinoma (RCC) is a highly vascularized tumor and prone to distant metastasis.
Sorafenib is the first targeted multikinase inhibitor and first-line chemical drug approved for …

Simple Summary The treatment of renal cancer is currently based on the use of
antiangiogenic drugs targeting the VEGF-A pathway and/or immunotherapy targeting …

Tyrosine kinase inhibitors (TKIs) are the most commonly used targeted therapeutics in clear-
cell renal cell carcinoma (ccRCC); however, drug resistance limits their utility and can lead …